KLRK1 and ovarian cancer: Barber and colleagues conducted another investigation to further elaborate on the applicability of T cells engineered with NKG2D-based chimeric receptors (designed in the previous study) by determining if adoptive transfer of these T cells could prolong the survival of ovarian cancer animal models, and whether the immune system of the treatment subjects could mount responses to antigens associated with ovarian cancer (123).